Lincoln National Corp acquired a new stake in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,359 shares of the medical research company’s stock, valued at approximately $265,000.
Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Exact Sciences by 4.4% in the third quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock valued at $541,823,000 after buying an additional 698,740 shares in the last quarter. Capital World Investors lifted its stake in shares of Exact Sciences by 17.2% in the 1st quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock valued at $383,652,000 after acquiring an additional 804,159 shares during the last quarter. Baillie Gifford & Co. boosted its holdings in shares of Exact Sciences by 2.5% during the 4th quarter. Baillie Gifford & Co. now owns 4,931,262 shares of the medical research company’s stock valued at $244,147,000 after acquiring an additional 118,025 shares in the last quarter. Eventide Asset Management LLC grew its position in Exact Sciences by 36.7% during the 3rd quarter. Eventide Asset Management LLC now owns 1,867,365 shares of the medical research company’s stock worth $60,671,000 after acquiring an additional 501,765 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Exact Sciences in the 3rd quarter worth about $50,684,000. 90.30% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, insider Jacob A. Orville sold 6,832 shares of the stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $60.29, for a total value of $411,901.28. Following the transaction, the insider now directly owns 16,423 shares in the company, valued at approximately $990,142.67. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Jacob A. Orville sold 6,832 shares of the company’s stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $60.29, for a total value of $411,901.28. Following the sale, the insider now owns 16,423 shares in the company, valued at approximately $990,142.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sarah Condella sold 954 shares of the company’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $65.59, for a total transaction of $62,572.86. Following the completion of the sale, the executive vice president now owns 85,166 shares in the company, valued at approximately $5,586,037.94. The disclosure for this sale can be found here. Insiders have sold a total of 63,126 shares of company stock worth $3,986,556 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.
Wall Street Analyst Weigh In
Exact Sciences Stock Performance
NASDAQ:EXAS opened at $78.73 on Thursday. The company has a fifty day moving average of $65.88 and a 200-day moving average of $57.29. The firm has a market capitalization of $14.03 billion, a P/E ratio of -22.24 and a beta of 1.41. The company has a quick ratio of 2.09, a current ratio of 2.38 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a twelve month low of $29.27 and a twelve month high of $80.75.
Exact Sciences (NASDAQ:EXAS – Get Rating) last issued its earnings results on Tuesday, May 9th. The medical research company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.37. The company had revenue of $602.00 million during the quarter, compared to the consensus estimate of $543.18 million. Exact Sciences had a negative return on equity of 19.76% and a negative net margin of 29.92%. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period last year, the business posted ($1.04) EPS. As a group, sell-side analysts anticipate that Exact Sciences Co. will post -2.76 EPS for the current year.
About Exact Sciences
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Featured Articles
- Get a free copy of the StockNews.com research report on Exact Sciences (EXAS)
- Occidental Petroleum: Will Buffet Buy More?
- 5 Best Healthcare Sector ETFs
- Electronic Arts Has Game But Can Share Price Move Higher?
- Wendy’s May Have Just Become A Value Play
- Rivian Leads EV Startups But Will The Stock Move Higher?
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
